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Abstract
Background: Data from HIV treatment programs in resource-limited settings show extensive rates of loss to follow-up
(LTFU) ranging from 5% to 40% within 6 mo of antiretroviral therapy (ART) initiation. Our objective was to project the
clinical impact and cost-effectiveness of interventions to prevent LTFU from HIV care in West Africa.
Methods and Findings: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) International model to
project the clinical benefits and cost-effectiveness of LTFU-prevention programs from a payer perspective. These programs
include components such as eliminating ART co-payments, eliminating charges to patients for opportunistic infection-
related drugs, improving personnel training, and providing meals and reimbursing for transportation for participants. The
efficacies and costs of these interventions were extensively varied in sensitivity analyses. We used World Health
Organization criteria of ,36 gross domestic product per capita (36 GDP per capita=US$2,823 for Co ˆte d’Ivoire) as a
plausible threshold for ‘‘cost-effectiveness.’’ The main results are based on a reported 18% 1-y LTFU rate. With full retention
in care, projected per-person discounted life expectancy starting from age 37 y was 144.7 mo (12.1 y). Survival losses from
LTFU within 1 y of ART initiation ranged from 73.9 to 80.7 mo. The intervention costing US$22/person/year (e.g., eliminating
ART co-payment) would be cost-effective with an efficacy of at least 12%. An intervention costing US$77/person/year
(inclusive of all the components described above) would be cost-effective with an efficacy of at least 41%.
Conclusions: Interventions that prevent LTFU in resource-limited settings would substantially improve survival and would
be cost-effective by international criteria with efficacy of at least 12%–41%, depending on the cost of intervention, based on
a reported 18% cumulative incidence of LTFU at 1 y after ART initiation. The commitment to start ART and treat HIV in these
settings should include interventions to prevent LTFU.
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Antiretroviral therapy (ART) has been proven to be highly
effective at reducing HIV/AIDS-related morbidity and mortality
in resource-limited settings [1–5]. Despite initial concerns about
practicality and operational feasibility, major international efforts
have been committed to expanding ART availability in sub-
Saharan Africa, where two-thirds of the HIV-infected persons in
the world reside [6]. As a result of this scaling-up process, the
number of HIV-infected persons treated with ART in sub-
Saharan Africa increased from only 100,000 in 2003 to 2.1 million
by the end of 2007—a 20-fold expansion over 4 y [7–12].
The benefits of the ART roll-out have been limited by a
substantial problem with loss to follow-up (LTFU) [13,14]. A large
proportion of HIV-infected patients initiating ART—up to 59% in
some settings—are lost to follow-up at some point after ART
initiation [7,11,15–18]. Poor retention in HIV care not only can
undermine the impact of scale-up, but can also lead to overstating
the performance of HIV programs, because individuals lost to
follow-up are generally sicker than those who are retained in care
and may therefore experience poorer long-term outcomes than
those who remain in care [19,20]. Moreover, mortality estimates
produced by active or passive surveillance programs are
dramatically different, often leading to overly optimistic results
from programs with passive follow-up [13,14,21,22].
Strategies to improve follow-up generally focus on efforts to
bring lost patients back into the health care system (e.g., by
outreach teams and collaboration with community organizations).
These measures to reverse LTFU have shown that many patients
identified as lost have already died [22–25]. Preventing LTFU
may, therefore, be more effective at improving outcomes. Because
such prevention programs may require sustained, long-term
investment, their economic feasibility is an important issue. Given
the lack of reported data on the actual intervention cost and
efficacy of LTFU prevention, we frame this analysis as a ‘‘what if’’
study to provide targets, in terms of both efficacy and cost, to
understand how the results of interventions to prevent LTFU
might fit into the broader context of HIV treatment [26]. We
sought to estimate the long-term clinical benefits and cost-
effectiveness of several plausible LTFU-preventive strategies
among HIV-infected persons receiving ART in Co ˆte d’Ivoire,
West Africa.
Methods
Analytic Overview
We coupled data from the Aconda program, an Abidjan-based
nongovernmental organization providing ART delivery in Co ˆte
d’Ivoire [11], with the Cost-Effectiveness of Preventing AIDS
Complications (CEPAC) International simulation model of HIV
disease and treatment [27–29]. We examined the effectiveness and
cost-effectiveness of alternative strategies to prevent LTFU in
HIV-infected persons initiating ART in Co ˆte d’Ivoire. We
considered several interventions with different levels of effective-
ness and costs, ranging from solely eliminating patient co-
payments for ART, to multimodal interventions that remove co-
payment for ART and medications used to treat AIDS-defining
illnesses, improve health care provider training, provide meals at
clinic visits, and offer transportation reimbursement. We com-
pared these interventions to the current standard of care in
Abidjan. We evaluated cost-effectiveness from the payer perspec-
tive, wherein all direct medical costs accruing to the organization
providing care (e.g., a health center making treatment available)
were considered in the analysis.
We used the model to project life expectancy and total costs of
care for HIV-infected persons treated with ART and who
remained in care, as well as for those who discontinued care at
1, 3, 6, or 12 mo after ART initiation. We estimated the
effectiveness of LTFU prevention interventions as the additional
survival benefits resulting from fewer HIV-infected persons
discontinuing ART prematurely. We estimated the cost-effective-
ness of the LTFU prevention interventions as the difference in
costs divided by the difference in life expectancy of the strategies,
with and without each LTFU prevention intervention. All costs
were reported in 2006 US$ using country-specific gross domestic
product (GDP) deflators [30] and the 2006 mean exchange rate
between the CFA franc and the US$ (US$1=CFA 540) (GDP and
36GDP are per capita) [31]. All costs and life expectancies were
discounted 3% per year [32]. We utilized guidelines from the
Commission on Macroeconomics and Health of the World Health
Organization (WHO) to determine whether specific LTFU
prevention interventions might be considered ‘‘cost-effective.’’ By
these guidelines, an intervention is considered ‘‘cost-effective’’ if its
cost-effectiveness ratio is below 36 the per capita GDP in a
country (US$2,823 in 2006 for Co ˆte d’Ivoire) and ‘‘very cost-
effective’’ if the cost-effectiveness ratio is below 16the annual per
capita GDP (US$941) [30,33].
The CEPAC International Model
The CEPAC International model is a widely published
computer simulation model of HIV disease that portrays natural
history and treatment strategies for HIV-infected individuals in
resource-limited settings [27–29]. In the model, each patient from
a simulated cohort of HIV-infected individuals transitions among
health states defined by CD4 count, HIV RNA level, history of
opportunistic infections (OIs), and ART use. In the absence of
ART, the natural history of HIV disease is determined by CD4
count decline, stratified by HIV RNA level, and CD4-specific rates
of HIV morbidity and mortality [34]. Monthly probabilities of OIs
and mortality rates are derived from the Agence Nationale de
Recherches sur le Sida et les He ´patites Virales (ANRS) 1203
Cotrame and the ANRS 1220 Primo-CI cohorts in Co ˆte d’Ivoire
[11,34,35]. ART reduces HIV RNA levels, increases CD4 counts,
and thereby confers a decrease in OI incidence and HIV-related
mortality [36]. In this analysis, the model assumes availability of
two lines of ART for persons in care. Patients receive first-line
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
ART consisting of nevirapine/lamivudine/stavudine and second-
line protease inhibitor (PI)-based ART consisting of lopinavir/
ritonovir/tenofovir/emtricitabine [11]. The standard of care
includes clinic visits every 3 mo, as well as in the month of any
acute OI.
Each simulated patient is assigned a CD4 count and HIV RNA
level at the time of entry into HIV care and is followed until the
time of death. Results from large numbers of these individual
simulations are aggregated to develop stable population estimates
of outcomes. Additional details on the model structure have been
published elsewhere [37,38].
Input Parameters for the Model
Cohort characteristics. Initial cohort characteristics in the
model are based on the demographic characteristics of HIV-
infected patients from the Aconda program sites in Abidjan, Co ˆte
d’Ivoire, a cohort participating in the international ANRS/
National Institutes of Health (NIH)-funded collaboration ART-
LINC of IeDEA [39]. The Aconda program relies on two different
types of HIV care delivery: (1) the CePReF clinic, a clinical
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public and private health care facilities, which include general
medical care as well as HIV-specific care. In this analysis, we
focused on people receiving HIV care at the public and private
general health care facilities. Patients receiving HIV treatment at
these facilities had a mean age of 37 y (standard deviation [SD],
9 y) and a mean CD4 count of 140/ml (SD, 116/ml) at the time of
ART initiation; 70% of them were female (Table 1).
Efficacy of ART. Virologic suppression with first-line,
NNRTI-based ART is estimated at 80.4% (unpublished data,
Co ˆte d’Ivoire). After 12 mo, patients switch to second-line therapy
if they experience a severe OI (excluding tuberculosis and bacterial
diseases), or if their CD4 count is observed to decrease $50%
from initial CD4 count or peak on-treatment CD4 [40]. In the
absence of specific data from Co ˆte d’Ivoire, we assumed that
virologic suppression on second-line, protease inhibitor-based
therapy was similar to that of first-line therapy (80.4% at 24 wk).
Patients on ART face the possibility of developing minor or major
toxicities, and patients who achieve virologic suppression have the
possibility of experiencing later virologic failure [41]. We assumed
that ART-related toxicities led to a drug substitution but not
discontinuation of treatment. In the base case, we assumed that
patients continued receiving second-line ART even after clinical
failure, until death.
Rates of LTFU. Patients were considered lost to follow-up if
(1) they were not known to be deceased, (2) they were not known
to have transferred to another care center, and (3) for patients
receiving ART, the time since last contact with the Aconda site
exceeded 3 mo [11]. For the base case estimate of LTFU rates, we
used the average cumulative incidence of 18% LTFU after 1 y
from the 18 Aconda program general care centers (excluding
CePReF) [11]. Among patients lost to follow-up, 12% were lost
during the first month, 19% between months 1–3, 25% between
months 3–6, and 44% between months 6–12 (Table 1). We used
the LTFU rate at CePReF (cumulative 1 y incidence of 11%), as
the basis for estimating the LTFU prevention program efficacy,
since this is an example of an HIV specialty center with
community outreach to patients at risk of being lost to follow-up
[21]. We used this reduction in LTFU rates (from 18% to 11%, or
40% efficacy, [18%–11%]/18%) as the anchor for basing the
efficacy of the different interventions. We examined a range of
10% to 75% efficacy to assess the impact on the outcomes.
We assumed that patients who were lost to follow-up
discontinued ART and experienced an accelerated CD4 count
decline until their HIV RNA returned to its pretreatment set
point, at which time their CD4 count continued to decline on the
basis of the natural history of HIV disease [42,43]. During this
time they were at increased risk of morbidity and mortality
compared to those patients not lost to follow-up.
We assumed that HIV-infected patients who are lost re-enter
care when they develop a WHO Stage 3–4 OI (excluding
tuberculosis and bacterial diseases) [40]. Since those who are lost
to care are subject to higher morbidity and mortality, only a
fraction of them will be able to return to care. By recognizing that
some patients will eventually re-enter care, even in the absence of
specific interventions, we deliberately introduce a conservative bias
against the LTFU-prevention programs in terms of the benefits
derived from retention in care [44].
Interventions for Preventing LTFU under Consideration
We considered four alternative interventions to prevent LTFU
(Table 1). These interventions are incremental in their content:
each subsequent intervention adds components and costs to the
previous one. The first intervention consists of shifting the costs
that patients pay (the patient’s co-pay in Co ˆte d’Ivoire of about
US$2/month, US$22/year) to the center providing ART. The
second intervention also eliminates the cost to patients for
Table 1. Model input parameters for an analysis of LTFU from
HIV programs in Abidjan, Co ˆte d’Ivoire.
Variable
Value
(SD) References
Baseline cohort characteristics
Age (y) 37 (9) [11]
CD4 count (cells/ml) 140 (116) [11]
Gender distribution (% female) 70 [11]
Lost to follow-up
a at 1 y (%) 18 [11]
Given lost, time at which LTFU occurred (%) — [11]
0–1 month 12 [11]
1–3 mo 19 [11]
3–6 mo 25 [11]
6–12 mo 44 [11]
Efficacy of antiretroviral therapy
Virologic suppression at 24 wk (%)
First-line therapy
b 80.4 Unpublished
data
Second-line therapy
b 80.4 Assumption
Probability of toxicity occurrence
Minor toxicity 0.77 [41]
Major toxicity 0.05 [41]
Probability of late virologic failure, monthly
c 0.012 —
Costs (2006 US$)
First-line ART, monthly
d 4.98 [48]
Second-line ART, monthly
d 55.98 [48]
Minor ART-related toxicity, per event 2.24 [38]
Major ART-related toxicity, per event 22.39 [38]
Co-trimoxazole, monthly 1.81 [38]
Routine care (range by CD4 count), monthly 20.87–28.57 [36,38]
CD4 count, per test 25.00 [37]
Intervention efficacies examined (%
reduction in LTFU)
10–75 —
Interventions examined — [47]
1. Elimination of the ART co-payment
(cost/person/year [US$])
22 [47]
2. Intervention 1 + providing OI-related
medications free to the patient (cost/
person/year [US$])
41 [47]
3. Intervention 2 + increased training for
health care workers (cost/person/year [US$])
53 [47]
4. Intervention 3 + reimbursing
transportation costs and providing
breakfast (cost/person/year [US$])
77 [47]
aLTFU, patients whose last contact with the care center was at least 3 mo prior
and who were not known to be dead or transferred to another care center.
Those who were lost to follow-up are assumed to re-enter care upon the
occurrence of any Stage 3–4 OI.
bFirst-line ART, non-nucleoside reverse transcriptase inhibitor-based regimen;
second-line ART, PI-based regimen. Efficacies are those reported for the ‘‘on
treatment’’ group.
cPatients who have achieved virologic suppression at 24 wk have a continuing
risk of later virologic failure.
dCost does not include monthly co-payment of approximately US$2.
doi:10.1371/journal.pmed.1000173.t001
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charged to the patients. This cost can impose a major financial
burden on HIV-infected patients; a recent study carried out in the
same setting revealed that on average the cost of the OI-related
drugs represents 11.8% of the family income [45]. These drugs
include but are not limited to cotrimoxazole, nystatin, paraceta-
mol, imodium, ibuprofen, and fluconazole [46]. The third
intervention adds the resources required to improve HIV care
skills among health care workers in public general health centers to
the level of those at the HIV-treatment center (CePReF). The
fourth intervention adds provision of breakfast or lunch and
reimbursement of transportation costs for patients attending
scheduled appointments.
The costs of the LTFU prevention programs were derived from
the UNAIDS/UNFPA Rapport National de la Co ˆte d’Ivoire as
well as personnel costs from the clinics and estimated real costs in
Abidjan. The costs per person per year for the four interventions
were US$22, US$41, US$53, and US$77 (Table 1 and Text S1 for
details) [47].
Cost of HIV care. The costs of ART regimens were based on
the lowest generic drug prices available for lower-income countries
for the most common first- and second-line regimens used in Co ˆte
d’Ivoire (US$4.98/month for first-line ART and US$55.98/month
for second-line ART, Table 1) [48]. The cost of co-trimoxazole
prophylaxis was estimated at US$1.81/month [38]. The cost of a
CD4 count was estimated at US$25/test, with tests performed
every 6 mo, at scheduled clinic visits [11]. Routine care costs in
addition to these specific items include outpatient visits, laboratory
tests, procedures including x-rays, and pharmacy [38]. Costs of
office visits and hospital stays were obtained from Yopougon
University Hospital in Abidjan [38]. The average cost per year per
person on ART is US$820, which includes the cost of ART,
prophylaxis, clinic visits, and laboratory monitoring, including
CD4 cell count.
Sensitivity Analyses
We varied several key parameters in the model across wide
ranges to examine which had the greatest effect on survival, cost,
and cost-effectiveness. We examined increases and decreases in the
efficacy of both first- and second-line ART, and evaluated
different strategies following second-line ART failure, including
remaining on failed second-line therapy, discontinuing second-line
ART after failure, or recycling first-line drugs. We also examined
the assumption that patients who were lost to follow-up re-enter
care at the time of a severe OI by considering that those lost to
follow-up never re-enter care, that they re-enter care upon the
occurrence of any OI, or that they re-enter with CD4 count ,50/
ml. In addition, we conducted a sensitivity analysis in which we
evaluated the role of HIV RNA monitoring on the cost-
effectiveness of LTFU prevention interventions. With respect to
costs, we increased as well as decreased the cost of first- and
second-line ART, the cost of treating OIs, and routine care costs.
We also varied baseline rates of LTFU.
Results
Per-Person Life Expectancy Losses Due to LTFU
The projected undiscounted life expectancy for an HIV-infected
patient initiating ART at age 37 y with CD4 140/ml and remaining
in care without LTFU is 201.5 mo (16.8 y, Table 2). For patients
lost to follow-up after 1, 3, 6, or 12 mo on ART, projected life
expectancyis estimatedat 84.0,87.3, 88.4, or 92.1 mo,respectively.
The life expectancy loss due to LTFU therefore ranges from
117.5 mo to 109.4 mo, or 58.3% to 54.3% of life expectancy,
depending on the timing of being lost. The projected life expectancy
of a typical patient lost to follow-up in the Aconda program is
estimated at 89.3 mo (7.4 y), which represents a loss of 112.2 mo
(9.4 y) compared to an ideal retention rate of 100%.
Community Impact of LTFU on Life Expectancy
With an 18% LTFU rate for the 6,704 patients receiving ART
through Aconda sites, 1,206 patients are lost by 1 y after ART
initiation.Ifeachpatientlosesanaverageof9.4 yoflife,thetotallife
expectancy loss for the cohort of HIV-infected patients currently in
Aconda community clinics due to LTFU would reach 11,336 y.
Cost-Effectiveness of Interventions Focused on LTFU
Prevention
As the efficacy in preventing LTFU increases, projected
discounted life expectancy increases, from 132.4 mo with 10%
efficacy to 141.3 mo with 75% efficacy. Because patients remain
in treatment longer on average with better retention, total lifetime
costs also increase. For the LTFU prevention program costing
US$22/person/year, per person lifetime costs range from
US$9,100 if the intervention is 10% effective to US$9,900 if the
intervention is 75% effective (Table 3). The cost-effectiveness
ratios of the LTFU intervention, compared to no intervention,
vary depending on the efficacy of the LTFU intervention. For the
US$22/person/year intervention the cost-effectiveness ratios
range from US$3,100 per year of life saved (YLS) at 10% efficacy
Table 2. Life expectancy loss due to LTFU in a cohort of patients in Abidjan, Co ˆte d’Ivoire.
Time from ART Initiation until LTFU Discounted
a Undiscounted
Life Expectancy (mo) Life Expectancy lost (mo) Life Expectancy (mo) Life Expectancy Lost (mo)
No LTFU 144.7 0 201.5 0
Months following ART initiation
0–1 64.0 80.7 84.0 117.5
2–3 66.5 78.2 87.3 114.2
4–6 67.6 77.1 88.4 113.1
7–12 70.9 73.9 92.1 109.4
At Aconda
b 68.4 76.3 89.3 112.2
aDiscounted at 3% per year.
bTaking into account timing of LTFU, given that patients were differentially lost to follow-up (12% lost after 1 mo, 19% lost after 3 mo, etc. See Table 1 for details).
doi:10.1371/journal.pmed.1000173.t002
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other LTFU prevention programs are presented in Table 3.
Guidance for the Prospective Evaluation of LTFU
Prevention Programs
Figure 1 shows the minimal efficacy at which a LTFU
prevention program might be considered cost-effective using three
different cost-effectiveness thresholds: 26,3 6, and 46per capita
GDP [33]. In settings with 18% LTFU at baseline, and using 36
per capita GDP as a threshold for ‘‘cost-effectiveness,’’ the LTFU
prevention program that costs US$22/person/year would be
considered cost-effective with an efficacy of at least 12%. LTFU
programs that cost US$53 or US$77 would be considered cost-
effective at a 36 per capita GDP threshold if they could reduce
LTFU rates by at least 28% and 41% (dashed line). At a 46per
capita GDP cost-effectiveness threshold, the LTFU prevention
intervention costing US$22/person/year would be considered
cost-effective if it could reduce LTFU rates by at least 8%, and the
intervention costing US$77/person/year would be considered
cost-effective at 27% efficacy (dotted line). At a 26GDP per capita
threshold, these interventions would be considered cost-effective at
efficacies of 23% and 86% (solid line).
Furthermore, Figure 1 shows that the intervention that costs
US$22/person/year and that provides a 12% reduction in rates of
LTFU would provide similar value as the more expensive (US$77/
person/year) intervention that is 41% efficacious, but the more
expensivestrategywouldprovidemorebenefitscomparedtothe less
expensive intervention, increasing overall life expectancy by 5.6
versus 1.6 discounted mo (unpublished data).
Sensitivity Analyses
We varied key parameters in the model to determine those with
the biggest impact on the results. We found that the cost of second-
line ART is the most important factor affecting the cost-
effectiveness of LTFU prevention interventions. Reducing the
cost of second-line ART to that of the cost of first-line ART
(US$4.98/month) decreased all cost-effectiveness ratios, so that the
US$41/person/year intervention would be cost-effective by the
,36 per capita GDP criterion, if it were at least 20% effective
(Figure 2A). When we assumed that patients stopped treatment
after second-line ART failure, instead of assuming that they
continued for the rest of their lives, the US$41/person/year
intervention would be cost-effective by the ,36per capita GDP
criterion, provided that it was at least 25% effective (Figure 2B).
Sensitivity analysis with HIV RNA monitoring available
resulted in slight increases in the cost-effectiveness ratios of LTFU
prevention strategies. The cost-effectiveness ratios increased by
6%–20%; the magnitude of the increase depended on the efficacy
and cost of the intervention, but the ratios remained within the
same thresholds for cost-effectiveness as the base case analysis
results.
The baseline rate of LTFU affects the cost-effectiveness of
LTFU prevention interventions. Figure 3 shows the cost-
effectiveness of four interventions of various efficacies and costs
at cumulative incidences of LTFU ranging from 5%–40% over
1 y. For example, in a program with 20% LTFU over 1 y, an
intervention with 10% efficacy at preventing LTFU that costs
US$22/person/year has a cost-effectiveness ratio less than 36per
capita GDP (Figure 3A). In the same setting, if the efficacy of the
Table 3. Lifetime costs, life expectancy, and cost-effectiveness of interventions to prevent LTFU in Aconda centers, Co ˆte d’Ivoire.
Effectiveness of Intervention (%
Reduction in LTFU)
Discounted per Person
Lifetime Costs
Discounted per Person Life
Expectancy (Mo)
Cost-Effectiveness Ratio
(US$/YLS)
No intervention US$8,800 131.0 —
US$22 intervention (/person/year)
10 US$9,100 132.4 US$3,100
25 US$9,300 134.4 US$1,800
50 US$9,600 137.9 US$1,400
75 US$9,900 141.3 US$1,200
US$41 intervention (/person/year)
10 US$9,300 132.4 US$4,900
25 US$9,500 134.4 US$2,600
50 US$9,800 137.9 US$1,800
75 US$10,100 141.3 US$1,500
US$53 intervention (/person/year)
10 US$9,500 132.4 US$6,100
25 US$9,600 134.4 US$3,000
50 US$9,900 137.9 US$2,000
75 US$10,200 141.3 US$1,700
US$77 intervention (/person/year)
10 US$9,700 132.4 US$8,400
25 US$9,900 134.4 US$4,000
50 US$10,200 137.9 US$2,500
75 US$10,500 141.3 US$2,000
Baseline LTFU rate is 18%. All cost-effectiveness ratios are computed on an incremental basis using the ‘‘no intervention’’ strategy as the comparator. See Methods and
Table 1 for details about each intervention.
doi:10.1371/journal.pmed.1000173.t003
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US$41 or US$53/person/year would have a cost-effectiveness
ratio less than 36 per capita GDP (Figure 3B). At 50% or 75%
efficacy of reducing LTFU, an intervention of any cost considered
(US$22–US$77/person/year) would have a cost-effectiveness ratio
less than 36per capita GDP (Figure 3C, 3D).
We also varied the assumptions about the behavior and
outcomes of patients who are lost to follow-up. In the base case,
all patients who are lost to follow-up re-enter care upon the
occurrence of a severe OI. This assumption results in 56.4% of
those lost to follow-up dying without returning to care. If all
patients re-enter care with any OI, the cost-effectiveness ratio for
the US$41/person/year intervention with 50% efficacy increases
from US$1,800/YLS to US$4,200/YLS. If all patients lost to
follow-up re-enter care when their CD4 count drops below 50
cells/ml, the cost-effectiveness ratio of the US$41/person/year
intervention (at 50% efficacy) is equivalent to that of the base case
(US$1,800/YLS). If those who are lost to follow-up never re-enter
care, their life expectancy is decreased to 2.5 y and the cost-
effectiveness ratio decreases to US$1,400/YLS.
Discussion
Using a simulation model for HIV treatment in Abidjan, Co ˆte
d’Ivoire, we estimate that LTFU from HIV treatment programs
leads to substantial losses in projected life expectancy—112.2 mo
on average for those lost during the first year of treatment. For a
program with about 6,700 patients, like the Aconda program in
Abidjan, these per patient numbers translate into over 11,000 y of
life lost—more than 1.5 y of life lost per person in the program. A
substantial proportion of these lost years of life could be saved by
implementing an effective LTFU prevention intervention. While
evidence on the efficacy of interventions to prevent LTFU is only
now beginning to accumulate [49], we find that such interven-
tions, if they cost less than US$22–US$53/person/year, would be
highly cost-effective under plausible assumptions of efficacy.
ART treatment programs in many resource-limited settings are
now reporting increasing problems with LTFU [14,19,50].
Evidence is also accumulating with regard to the causes of LTFU
in resource-limited settings and programs to reduce LTFU have
focused on either reducing costs to patients (ART co-payments, OI
costs, transportation costs) or increasing the benefits to patients for
their visits (free lunch, improved service because of better trained
personnel). Although the WHO has recommended free access to
ART, many countries have been unable to deliver such programs
[51,52]. Data from the ART-LINC Collaboration, including the
cohorts in Co ˆte d’Ivoire, as well as programs in Botswana and
Tanzania, have found that charging a fee for care is associated
with increased LTFU and increased mortality [13,50,53,54].
Recent data from Cameroon show that patients’ self-reported
financial difficulty in purchasing ART was associated with lower
adherence and lower CD4 count after 6 mo on treatment [55]. In
Figure 1. Threshold efficacy, cost, and life expectancy associated with LTFU prevention interventions in Co ˆte d’Ivoire. This figure
describes threshold efficacy for alternative willingness to pay thresholds, shown in blue (26per capita GDP), green (36per capita GDP), and orange
(46per capita GDP). Triangles represent efficacy thresholds for LTFU interventions at US$22/person/year, squares at US$41/person/year, circles at
US$53/person/year, and diamonds at US$77/person/year. The vertical axis shows the per person discounted life expectancy and the horizontal axis
shows the per person discounted lifetime cost. The red dot in the lower left corner represents the per person life expectancy and lifetime cost in a
program with no LTFU intervention.
doi:10.1371/journal.pmed.1000173.g001
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that programs that did not require patients to pay for treatment
had higher retention rates at 6 mo compared to programs
requiring partial or full payment [14]. Recent data from Kenya
suggest that providing ART free to patients led to a 57% decrease
in LTFU [56]. On the basis of these recent data from Kenya, in
August 2008, the government of Co ˆte d’Ivoire mandated ART
free to all patients [57]. Transportation costs may also play an
important role in determining outcomes in those living farther
from their site of care [58–60]. Studies in Burkina Faso and Mali
found decreased viral suppression in patients living farther from
the clinic, suggesting follow-up as a major determinant of success
[61]. Food insecurity also poses a challenge to HIV-infected
patients who have competing priorities of securing food as well as
HIV treatment. Providing food at the time of the clinic visit may
encourage some patients to attend their clinic appointment or to
get their medications [62].
For example, the CePReF center in the Aconda program, which
utilized a team of social workers and people living with HIV/
AIDS to make telephone calls or home visits to patients who did
not keep their scheduled appointments, had rates of LTFU at 1 y
that were 40% lower than the general health care centers in the
program. At an intervention cost of US$22–US$53/person/year,
the cost-effectiveness ratio of such an intervention is less than
US$2,800/YLS, which is ,36 the per capita GDP in Co ˆte
d’Ivoire.
Since the efficacy of each individual component of the LTFU
prevention interventions considered in the analyses reported here
is unknown, we have ordered the interventions in terms of what
may be most effective and feasible. However, parts of each
intervention (or interventions not specified here) could be
implemented individually or in different combinations than we
proposed. We prioritized eliminating ART co-payments as the first
step because this has been previously shown to be associated with
better outcomes in several studies in Africa, and because it is
increasingly considered feasible.
The LTFU prevention interventions considered in this analysis
focused on reducing costs to the patient and improving health care
workers’ skills, but other strategies to prevent LTFU may also be
considered as part of an effective LTFU prevention intervention.
For example, health care workers may send patients text messages
to remind them of their upcoming clinic appointments, or make
phone calls to patients who have recently missed appointments.
Another possible intervention would involve assigning a health
system navigator to patients to provide personalized support and
help coordinate their care, including ongoing clinic visits. One
recently presented study showed the positive impact of frequent
monitoring by dedicated nurses on mortality reduction in the early
months of ART among high-risk patients initiating treatment in
resource-limited settings [63].
We found that settings with higher rates of LTFU have the most
to gain from LTFU prevention interventions. However, this
analysis shows that even in settings with moderate LTFU rates,
interventions to decrease LTFU may be cost-effective. However, it
is critical to ensure that, from a programmatic perspective,
decision makers not reward poor rates of follow-up with greater
Figure 2. Sensitivity analysis on cost and efficacy of interventions to prevent LTFU with 18% baseline LTFU. (A and B) Represent the
cost-effectiveness of LTFU prevention strategies as a function of cost (columns) and efficacy (rows). (A) Illustrates the scenario where the cost of
second-line ART is decreased to the cost of first-line ART (US$4.98/month, excluding patient co-payment). (B) Shows the scenario of stopping second-
line ART after failure instead of continuing ineffective therapy. The light blue areas represent combinations of cost and efficacy of LTFU prevention
strategies under each ART cost composition that ensure cost-effectiveness of LTFU strategies below 26per capita GDP. The yellow area represents
combinations of cost and efficacy of LTFU interventions that produce cost-effectiveness ratios between 26and 36per capita GDP. The red area
represents scenarios where the cost-effectiveness ratios of LTFU interventions exceed 36per capita GDP.
doi:10.1371/journal.pmed.1000173.g002
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create. Cost-effectiveness can inform programmatic resource
allocation, but should not be the only factor governing such
decisions.
In sensitivity analyses, the cost of ART, particularly expensive
second-line ART, affected cost-effectiveness the most. One of the
determinants of the importance of the cost of second-line ART is
the fact that in the base case analysis, patients continue receiving
second-line ART, even after clinical failure. In this analysis we
assumed that ART is continued after second-line failure for its
independent protective effect, and this strategy was cost-effective.
Decisions about potentially stopping ART after clinical failure,
particularly in areas where drug supply may be insufficient, should
be the focus of additional investigation.
As of 2007, only 5% of all people receiving ART in low- and
middle-income countries were estimated to be receiving a second-
line regimen [64]. However, these numbers are expected to
increase greatly in future years as programs continue to be rolled
out and patients have been on first-line regimens longer. The
WHO recommends that countries establish national treatment
guidelines with specific second-line regimens, and they specified
the highest priority second-line regimen to consist of a ritonavir-
boosted PI (lopinavir or atazanavir) and two nucleoside reverse
transcriptase inhibitors (NRTIs, abacavir/didanosine or tenofo-
vir/emtricitabine). In order to ensure continued access to life-
saving HIV treatment, decreasing the costs of second-line ART
should be a major priority.
While this analysis showed that LTFU prevention strategies
carry substantial survival benefits and can be cost-effective
according to international standards, it is critical to combine
these interventions with programs that maximize timely linkage to
care and ART initiation in patients newly diagnosed with HIV.
The CEPAC model estimate of life expectancy in HIV-infected
individuals of 16.8 y (undiscounted) receiving ART may seem high
at first glance, but it lies within the plausible values for Co ˆte
d’Ivoire. According to the most recent WHO life tables (2006)
[65], the average additional life expectancy for someone 35–39 y
old (the range that includes the mean age at ART initiation used in
the current analysis) is 30.2 y, which includes both HIV-infected
and HIV-uninfected individuals. This positions the CEPAC-based
estimate for HIV-infected individuals well within the plausible
range. In contrast, HIV-infected patients who initiate ART at an
average age of 37 y with a CD4 cell count of 140 cells/ml who are
lost to follow-up during the first year after ART initiation and did
not return to care, have an estimated life expectancy of only 2.6 y
(undiscounted).
There are several limitations to this study. First, the data are
from sites in Abidjan, Co ˆte d’Ivoire, and may not be generalizable
to all West African countries or all resource-limited settings.
Second, our effort to estimate the impact of adding infrastructure
to treatment programs with higher LTFU rates, to achieve the
lower rates seen at HIV-specific centers, may not fully capture the
skills that exist at specialty centers, which allow them to achieve
better outcomes. In this analysis, we did not account for any
benefits associated with improved health care workers’ skills
beyond patient retention. More broadly, because of the lack of
data on interventions to prevent LTFU and the efficacy of such
interventions, this remained a ‘‘what if’’ analysis, with wide-
ranging intervention-projected efficacies of 10%–75%. More data
on the actual efficacies of LTFU prevention interventions are
needed to help decision makers better understand the impact of
such interventions in their treatment programs.
While in reality, characteristics of patients who are lost to
follow-up may differ from those who remain in treatment, the
Figure 3. Cost-effectiveness of interventions to prevent LTFU, stratified by intervention cost. This figure shows the cost-effectiveness
ratios of interventions ranging in efficacy from 10%–75%, stratified by cost (US$22, US$41, US$53, and US$77/person/year) and at cumulative
incidences of LTFU ranging from 5%–40% over 1 y.
doi:10.1371/journal.pmed.1000173.g003
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of being lost to follow-up, independent of age, gender, and stage of
HIV disease. We also did not account for LTFU occurring more
than 1 y after ART initiation, since it has been shown that the
highest rates of LTFU occur soon after ART initiation.
LTFU is a critically important problem in many HIV treatment
programs in resource-limited settings. We found that interventions
to prevent LTFU, using specific strategies and cost data from Co ˆte
d’Ivoire, are likely to provide excellent value if they are moderately
effective, and would lead to important survival benefits. The
development, testing, and dissemination of effective programs to
prevent LTFU from HIV treatment programs in resource-limited
settings should be a major priority.
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Background. Acquired immunodeficiency syndrome (AIDS)
has killed more than 25 million people since the first
reported case in 1981. Currently, about 33 million people are
infected with the human immunodeficiency virus (HIV),
which causes AIDS. Two-thirds of people infected with HIV
live in sub-Saharan Africa. HIV infects and destroys immune
system cells, thereby weakening the immune system and
rendering infected individuals susceptible to infection. There
is no cure for HIV/AIDS. Combination antiretroviral therapy
(ART), a mixture of antiretroviral drugs that suppress the
replication of the virus in the body, is used to treat and
prevent HIV infection. ART is expensive but major
international efforts by governments, international
organizations, and funding bodies have increased ART
availability. According to World Health Organization (WHO)
estimates, at least 9.7 million people in low- and middle-
income countries need ART and as of 2007, 3 million of those
people had reliable access to the drugs.
Why Was This Study Done? Although ART is an effective
treatment for HIV, a large number of individuals who initiate
ART do not receive long-term follow-up care. These patients
are generally sicker and have a worse long-term outcome
than those who receive follow-up care. Loss to follow up
(LTFU) is a significant problem that can undermine the
benefits of expanding ART availability. Strategies to improve
follow up concentrate on bringing lost patients back into the
health care system, but such patients often die before they
can be contacted. Prevention of LTFU might be a better
strategy to improve HIV care after ART initiation, but there is
little information available on which specific interventions
might best accomplish this goal.
What Did the Researchers Do and Find? Given the lack
of reported data on the actual costs and effectiveness of
LTFU prevention, the researchers used a model to estimate
the clinical impact and cost-effectiveness of several possible
strategies to prevent LTFU in HIV-infected persons receiving
ART in Co ˆte d’Ivoire, West Africa. The researchers used the
previously developed Cost-Effectiveness of Preventing AIDS
Complications (CEPAC) computer simulation model and
combined it with data from a program of ART delivery in
Abidjan, Co ˆte d’Ivoire. They then projected the clinical
benefits and the cost required to attain a given level of
benefit (cost-effectiveness ratio) of different LTFU-prevention
strategies from the perspective of the payer (the
organization that pays all the medical costs to provide
care). Several interventions were considered, including
reducing costs to patients (eliminating patient co-
payments and paying for transportation) and increasing
services to patients at their visits (improving staff training in
HIV care, and providing meals at clinic times). LTFU was
predicted to cause a 54.3%–58.3% reduction in the
estimated life expectancy beyond age 37; patients
continuing HIV care were predicted to live a further 144.7
months whie those lost to follow up by 1 year after ART
initiation were predicted to live only for a further 73.9–80.7
months. LTFU-prevention strategies in the Co ˆte d’Ivoire were
deemed to be cost-effective if they cost less than $2,823
(which is 36gross domestic product per capita) per year of
life saved. The efficacy and cost of the different LTFU-
prevention strategies varied in the analyses; stopping ART
co-payment alone would be cost-effective at a cost of $22/
person/year if it reduced LTFU rates by 12%, while including
all the LTFU-prevention strategies described would be cost-
effective at $77/person/year if they reduced LTFU-rates by
41%.
What Do These Findings Mean? The findings suggest
that moderately effective strategies for preventing LTFU in
resource-limited settings would improve survival, provide
good value for money, and should be used to improve HIV
treatment programs. Although modeling is valuable to
explore the costs and effectiveness of LTFU-prevention
strategies it cannot replace the need for more reported
data to shed light on problems leading to LTFU and the
prevention strategies required to combat it. Also, Co ˆte
d’Ivoire might not be representative of all West African
countries or resource-limited settings. A similar analysis
using data from other ART programs in different countries
would be useful to provide better understanding of the
impact of LTFU in HIV treatment programs. Finally, the
research highlights the cost of second-line ART (a new
antiretroviral drug combination for patients in whom first-
line treatment fails) as a crucial issue. It is estimated that 5%
of all people receiving ART in low- and middle-income
countries receive second-line ART and these numbers are
expected to increase. Second-line ART had major effects on
cost-effectiveness, and a reduction in the cost of this
treatment is critical in order to guarantee continued access
to HIV treatment.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000173.
N This study is further discussed in a PLoS Medicine
Perspective by Gregory Bisson and Jeffrey Stringer
N WHO provides information on disease prevention, treat-
ment, and HIV/AIDS programs and projects
N The UN Millennium Development Goals project site
contains information on worldwide efforts to halt the
spread of HIV/AIDS
N aidsmap, a nonprofit, nongovernmental organization,
provides information on HIV and supporting those living
with HIV
Preventing HIV Program Loss to Follow-Up
PLoS Medicine | www.plosmedicine.org 11 October 2009 | Volume 6 | Issue 10 | e1000173